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http://dx.doi.org/10.1016/j.ccr.2013.02.003SUMMARYActivating mutations in BRAF are the most common genetic alterations in melanoma. Inhibition of BRAF
by small molecules leads to cell-cycle arrest and apoptosis. We show here that BRAF inhibition also induces
an oxidative phosphorylation gene program, mitochondrial biogenesis, and the increased expression of
the mitochondrial master regulator, PGC1a. We further show that a target of BRAF, the melanocyte lineage
factor MITF, directly regulates the expression of PGC1a. Melanomas with activation of the BRAF/
MAPK pathway have suppressed levels of MITF and PGC1a and decreased oxidative metabolism.
Conversely, treatment of BRAF-mutated melanomas with BRAF inhibitors renders them addicted to oxida-
tive phosphorylation. Our data thus identify an adaptive metabolic program that limits the efficacy of
BRAF inhibitors.INTRODUCTION
Activating mutations in the BRAF protein kinase are the most
common genetic alterations in melanoma, found in 50% of
tumors (Davies et al., 2002; Curtin et al., 2005). The most
frequent BRAF mutation is the substitution of valine at position
600 by glutamic acid (BRAF V600E) that results in the constitu-
tive activation of its serine/threonine kinase activity and sus-
tained activation of the mitogen-activated protein kinase
(MAPK) signal transduction pathway (Davies et al., 2002; Wan
et al., 2004). BRAF directly phosphorylates the dual-specificity
kinases MEK1 and MEK2, which in turn phosphorylate and acti-Significance
BRAFmutations are themost common genetic aberrations inm
genesis are poorly understood. Here, we show that activated B
oxidative phosphorylation through the actions of themelanocyt
PGC1a. BRAF inhibitors, which transiently suppress melanoma
phosphorylation. This addiction to oxidative phosphorylation i
suggests that mitochondrial inhibitors should be evaluated in
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overexpression and knockdown experiments to be a critical
mediator of melanomagenesis. In mice, activation of BRAF in
combination with deletion of the tumor suppressor genes
PTEN or INK4A leads to melanoma with complete penetrance
(Dankort et al., 2009; Dhomen et al., 2009). Conversely, treat-
ment of BRAF mutant melanomas in vitro with chemical inhibi-
tors of BRAF or MEK1/MEK2 promotes cell-cycle arrest and
apoptosis (Hingorani et al., 2003; Karasarides et al., 2004; Hoe-
flich et al., 2006; Wellbrock et al., 2008). Moreover, the BRAF
inhibitor vemurafenib (PLX4032) leads to tumor regression and
improved overall survival in patients whose melanomas haveelanoma, but themechanisms bywhich they promote onco-
RAF promotes metabolic reprogramming by suppression of
e lineage factorMITF and themitochondrial master regulator
growth in vitro and in patients, induce PGC1a and oxidative
n melanomas treated with BRAF-targeted therapy therefore
combination with BRAF pathway inhibitors in vivo.
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for patients with metastatic melanoma (Flaherty et al., 2010;
Chapman et al., 2011; Sosman et al., 2012). Despite the promise
and dramatic initial effects of BRAF inhibitors in the clinic,
patients eventually relapse within a few months, suggesting
that combination therapies may be needed to overcome intrinsic
or acquired resistance (Gray-Schopfer et al., 2007; Poulikakos
and Rosen, 2011).
Althoughmelanomas with BRAFmutations have constitutively
active growth signals, how they sustain their growth in the setting
of nutrient scarcity is not well understood. In 1930, OttoWarburg
proposed that cancer cells have a high rate of glycolysis as
compared to oxidative metabolism even under conditions of
high oxygen, a phenomenon known as the Warburg effect (War-
burg, 1956; Vander Heiden et al., 2009). Oxidative phosphoryla-
tion depends on the ability of functionally intact mitochondria to
metabolize oxygen, whereas glycolysis can occur independently
of mitochondria. Warburg theorized that this metabolic switch
facilitated the uptake and incorporation of nutrients that were
required for cellular proliferation. Although poorly understood
in melanoma, the molecular mechanisms of metabolic reprog-
ramming in cancer have been described in other tumor types.
TP53-deficient tumor cells have diminished levels of the genes
TIGAR and SCO2, which regulate glycolysis and assembly of
the mitochondrial cytochrome c oxidase complex, respectively
(Bensaad et al., 2006; Matoba et al., 2006). Similarly, the dysre-
gulation of the proto-oncogene MYC leads to profound effects
on tumor metabolism through multiple mechanisms (reviewed
in Dang, 2012).
These observations have raised the possibility of targeting key
metabolic pathways to inhibit cancer growth. Yun et al. demon-
strated that several colorectal cancers with KRAS or BRAF
mutations have increased glucose uptake and glycolysis and
survived better in low-glucose conditions compared to nonmu-
tated cell lines (Yun et al., 2009). Suppression of glycolysis
with 3-bromopyruvate (a nonactive intermediary in the glycolysis
pathway) reactivates mitochondrial metabolism in tumor cells,
induces their selective killing, and suppresses cancer growth.
Similarly, suppression of glycolysis by inhibiting conversion of
pyruvate to lactate enhances oxidative phosphorylation and
suppressed the growth of breast cancer cell lines (Fantin et al.,
2006; Bonnet et al., 2007). Thus, whereas metabolic reprogram-
ming is commonly found in cancer, themechanism and details of
metabolic alterations in melanoma are unknown.
Mitochondrial biogenesis and oxidative phosphorylation are
well known to be controlled by the members of the peroxisome
proliferator-activated receptor g coactivator 1 (PGC-1) family
of transcriptional coactivators (PGC1a, PGC1b, PPRC1) (Lin
et al., 2005a; Finck and Kelly, 2006; Handschin, 2009; Leone
and Kelly, 2011). The best-studied PGC-1 family member,
PGC1a, potently activates coordinated gene expression
programs by interacting with transcription factors, the basal
transcriptional machinery, histone-modifying enzymes, and the
RNA-splicing machinery. PGC1a drives mitochondrial biogen-
esis in multiple contexts, including brown and white adipocytes
(Wu et al., 1999; Uldry et al., 2006), skeletal muscle (Lin et al.,
2002), and the heart (Lehman et al., 2000). PGC1a mRNA
expression is sensitive to numerous signaling inputs that have
been implicated in cancer biology (Herzig et al., 2001; Yoonet al., 2001; Chinsomboon et al., 2009; Arany et al., 2008).
PGC1b shares significant sequence homology and functional
overlap with PGC1a, including the activation of mitochondrial
biogenesis and oxidative phosphorylation, but also has several
distinct functions in different tissues (Lin et al., 2005b; Uldry
et al., 2006; Wolfrum and Stoffel, 2006). The regulation of
PGC1b has been less extensively studied. Although little is
known about the role of the PGC-1s in melanoma, they have
recently been implicated in metabolic shifts in breast cancer
cells and colon cancers (Eichner et al., 2010; Bhalla et al.,
2011; Sahin et al., 2011; Wang and Moraes, 2011; Girnun,
2012; Klimcakova et al., 2012). Here, we comprehensively eval-
uate the effect of BRAF pathway activation on metabolic gene
expression and function in melanoma.
RESULTS
BRAF Regulates Metabolic Reprogramming
of Melanomas
Themechanisms bywhich oncogenic BRAF promotes oncogen-
esis are incompletely understood. Gene set enrichment analysis
(GSEA) provides a bioinformatics approach to identify gene
signatures among microarray data sets that are induced or sup-
pressed as small coordinated changes in individual genes (Moo-
tha et al., 2003). In order to identify gene expression programs
altered by oncogenic BRAF, we evaluated previously published
gene expression profiles of BRAF mutant melanomas treated
with the BRAF inhibitor vemurafenib (Joseph et al., 2010). As
shown in Figure 1A, treatment of BRAF mutant melanomas
with vemurafenib resulted in significant increases in the expres-
sion of the citric acid cycle gene set (Figure 1A) as well as
multiple oxidative phosphorylation and ATP synthesis gene
sets (Table S1 available online). Similarly, melanoma cells
treated with PD0325901, a preclinical inhibitor of the MEK1/
MEK2 protein kinases (Pratilas et al., 2009; Joseph et al.,
2010), also exhibited a trend toward induction of the citric acid
cycle and oxidative phosphorylation gene sets (Table S2). In
contrast, we did not find enrichment of oxidative phosphoryla-
tion, or citric acid cycle gene sets in BRAF mutant nonmelano-
mas treatedwith PD0325901 (Table S3).We validated the effects
of vemurafenib on OXPHOS gene expression in three melanoma
cell lines by quantitative PCR (qPCR) (Figures S1A–S1C).
To directly evaluate the effect of BRAF inhibition on oxidative
phosphorylation and mitochondrial number and function, we
treated melanoma cell lines with PLX4720, a preclinical analog
of vemurafenib (Tsai et al., 2008). PLX4720 increased the mito-
chondrial density of two BRAF mutant melanomas as detected
by MitoTracker Green, which localizes to mitochondria indepen-
dent of membrane potential. PLX4720 did not affect the mito-
chondrial density of MeWo cells that are BRAF wild-type (Fig-
ure 1B). PLX4720 also induced MitoTracker Red fluorescence,
a measure of mitochondrial activity and mass (Figure 1C), and
increased the production of mitochondrial oxidative stress
measured by the MitoSOX fluorescence assay (Figure 1D). To
confirm these findings, we also evaluated mitochondrial number
by electron microscopy after treatment of the BRAF mutant
melanoma cell line UACC62 with PLX4720. As seen in Figures
1E and S1D, inhibition of BRAF led to a significant increase in
the number of mitochondria per cell.Cancer Cell 23, 302–315, March 18, 2013 ª2013 Elsevier Inc. 303
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Figure 1. BRAF Inhibitors Induce Mitochondrial Biogenesis and Oxidative Metabolism
(A) GSEA plot of melanoma cells treated with vemurafenib showing the most significantly changed gene set. FDR, false-discovery rate; ES, enrichment score.
(B) MitoTracker Green fluorescence of BRAF mutant (UACC-62 and UACC-257) or BRAF wild-type (MeWo) melanoma cell lines treated with PLX4720 (1 mM,
72 hr) and subjected to analysis by flow cytometry.
(C and D) MitoTracker Red fluorescence (C) or MitoSOX fluorescence (D) of UACC-62 cells treated with PLX4720.
(E) Electron micrographs of UACC-62 cells treated with PLX4720 or vehicle control. Representative photographs of cells at 22,0003 (upper panel) or 44,0003
(lower panel) are shown. Arrowhead indicates a representative mitochondrion.
(F) Lactate levels in media conditioned from the indicated cell lines treated with PLX4720 or vehicle control for 16 hr.
(G) Cells in (F) were concomitantly evaluated for ERK activity by western blotting using phospho-ERK antibodies.
Error bars represent SEM of at least three independent replicates. ***p < 0.001; **p < 0.01. ns, not significant.
See also Tables S1–S3 and Figure S1.
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can be due to the shunting of pyruvate away from oxidative
phosphorylation (Vander Heiden et al., 2009). In linewith our find-
ings above, PLX4720 reduced lactate levels in all BRAF mutant
melanomas evaluated (Figure 1F). Lactate levels did not change
upon treatment of a melanoma cell line that does not contain the
BRAF mutation, consistent with the inability of PLX4720 to
suppress ERK signaling in these cells (Figure 1G). Collectively,
our data suggest that BRAF suppresses oxidative phosphoryla-
tion gene expression and mitochondrial density in melanoma.
BRAF and MAPK Activation Suppresses PGC1a
Because oxidative phosphorylation depends on mitochondrial
number and activity, their alteration may contribute to altered
tumor metabolism. Candidate pathways, which physiologically
regulate mitochondrial content and function, include the mito-
chondrial transcription factors A (TFAM) and B (TFB1M,
TFB2M), nuclear respiratory factor 1 (NRF1), GA binding proteins
(GABPA,GABPB2), peroxisome proliferator-activated receptors304 Cancer Cell 23, 302–315, March 18, 2013 ª2013 Elsevier Inc.(PPARa, PPARb), PPAR-g coactivators (PGC1a, PGC1b), and
PGC1-related coactivator 1 (PPRC1) (reviewed in Kelly and
Scarpulla, 2004).
We observed that BRAF(V600E) expression suppressed
PGC1a, a well-known regulator of mitochondrial metabolism in
the microarray data sets above. To validate these observations,
we treated a series of BRAF mutant melanomas and nonmela-
noma cell lines with PLX4720 and evaluated the effect on
PGC1a mRNA (Figure 2A). In all melanomas with BRAF muta-
tions, PLX4720 induced 3- to 14-fold increases in PGC1a
mRNA. We did not observe any changes in the expression of
PGC1a in a BRAF wild-type MeWo cell line treated with
PLX4720. Surprisingly, we did not observe any effects of
PLX4720 on PGC1a expression in two BRAF mutant colon
cancer cell lines, despite suppression of ERK phosphorylation
similar to that seen in melanomas (Figure 2B). We did not
observe any change in PGC1b mRNA upon treatment with
PLX4720 or any effects in a BRAF wild-type melanoma over
24 hr (Figures S2A and S2B). These data suggested that there
EA
B
D
C
PLX4720
pERK
ERK
– + – + – + – + – + – + – +
– + – + – + – +
Melanoma Colon cancer
BRAFV600E 
Colon Cancer
BRAFV600E
Melanoma
***
******
*
F
m
el
an
om
a
pERK
ERK
****
****
* *
N
or
m
al
iz
ed
 
P
P
A
R
G
C
1A
 m
R
N
A
N
or
m
al
iz
ed
 
P
P
A
R
G
C
1A
 m
R
N
A
N
or
m
al
iz
ed
 
P
P
A
R
G
C
1A
 m
R
N
A
0
0
10
20
30
5
10
15
20 Control
PLX4720
Control
PD0325901
PD0325901
M
eW
o
U
A
C
C
62
U
A
C
C
25
7
M
A
LM
E
M
14
W
D
ir
C
O
LO
20
1
U
A
C
C
62
M
A
LM
E
M
14
M
eW
o
6
4
2
0
M
D
A
46
8
H
16
50
A
43
1
B
T4
74
B
K
B
R
3
C
O
LO
20
5
H
T2
9
M
A
LM
E
3M
S
K
M
E
L1
S
K
M
E
L5
S
K
M
E
L1
9
S
K
M
E
L2
8
P
PA
R
G
C
1A
B
C
L2
A
1
M
IT
F
M
R
E
G
M
LA
N
A
TR
Y
P
1
TR
P
M
1
R
A
B
27
A
0.
50
0.
52
1.
0
0.
74
0.
80
0.
71
0.
38
0.
69
Figure 2. BRAF Inhibitors Induce PGC1a Expression
(A and B) PGC1amRNA (A) and phospho-ERK levels (B) in melanoma or colon
cancer cells treated with PLX4720 (1 mM) for 24 hr.
(C and D) PGC1amRNA (C) and ERK activity (D) in melanoma cells treated with
the MEK inhibitor PD0325901 (10 nM) for 24 hr.
(E) Microarray analysis (GSE10086) of PGC1a mRNA in cell lines treated with
10 nM PD0325901 for 24 hr.
(F) Comparison of PGC1a mRNA with MITF, melanocytic markers, and MITF
targets in 105 melanoma cell cultures (Hoek et al., 2006). Pearson correlation
coefficient is shown below each gene.
Error bars represent SEM of at least three independent replicates. ****p <
0.0001; ***p < 0.001; *p < 0.01.
See also Figure S2.
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BRAF Regulates Metabolism via PGC1a and MITFmight be lineage-specific differences in the regulation of PGC1a
by BRAF. To validate our findings using a structurally unrelated
small molecule, we treated several melanoma cell lines with
the MEK inhibitor PD0325901. Induction of PGC1a mRNA (Fig-
ure 2C) and suppression of ERK phosphorylation (Figure 2D)were seen in all cell lines tested including the BRAF wild-type
melanomaMeWo, suggesting that the BRAF/MEK/ERK pathway
regulates PGC1a expression in melanoma cells. These results
were also confirmed with additional NRAS mutant melanoma
cell lines treated with a MEK1/MEK2 inhibitor (Figures S2C and
S2D). Finally, we evaluated the expression of PGC1a in an inde-
pendent data set of A375melanoma cells selected for resistance
to BRAF inhibitors (Greger et al., 2012). We observed that
PGC1a expression was 10-fold lower in cells that had acquired
resistance to BRAF inhibitors (Figure S2E), likely reflecting their
higher demonstrated basal MAPK activity.
We also interrogated a publicly available microarray of 12
breast, lung, colon, and melanoma cell lines treated with
PD0325901 (Joseph et al., 2010). Suppression of MEK only
affected PGC1a mRNA in melanoma cell lines (Figure 2E; p <
0.0001), suggesting that the regulation of PGC1a mRNA by the
BRAF/MEK/ERK pathway is unique to the melanocytic lineage.
Consistent with our results, we found that PGC1a expression
was significantly correlated with melanocyte-specific antigen
expression in a data set comprising of 105 melanoma cell
cultures (Hoek et al., 2006) (Figure 2F).
PGC1a mRNA Is Directly Regulated by the MITF
Transcription Factor
To elucidate how BRAF may regulate PGC1a, we compared the
expression pattern of all human transcription factors to PGC1a in
a large microarray data set of short-term melanoma cultures (Lin
et al., 2008). Among the transcription factors whose expression
most closely paralleled PGC1a, we observed that both transcrip-
tion factor EB (TFEB) and the microphthalmia-associated tran-
scription factor (MITF) were significantly associated with
PGC1a expression (q < 0.001) (Figure 3A). Both TFEB and
MITF aremembers of a four-member family of distinctly encoded
transcription factors (TFEB, TFEC, TFE3, and MITF) that share
a common structure, binding recognition sequence, and function
(Haq and Fisher, 2011). Whereas TFEB, TFEC, and TFE3 are
ubiquitously expressed, MITF is largely restricted to the melano-
cytic lineage. The correlation of PGC1a to MITF was therefore
interesting in light of our data suggesting BRAF regulation of
PGC1a in melanoma, but not in other lineages (see Figures 2A
and 2E). MITF expression correlated with PGC1a as shown
above (see Figure 2F).
We therefore evaluated the requirement of TFE3, TFEB, and
MITF for the expression of PGC1a by siRNA. In both M14 mela-
noma cells and primary human melanocytes, suppression of
MITF but not TFEB or TFE3 (Figures 3B and S3A) led to a signif-
icant suppression ofPGC1a (Figures 3C andS3B) despite similar
knockdown efficiency. We were unable to reliably detect TFEC
expression in the cell lines tested (data not shown). MITF
suppression in two other melanoma lines also significantly
reduced PGC1a expression (Figure S3C), which was validated
using two independent shRNAs (Figure S3D).
In silico analysis of the PGC1a promoter identified three puta-
tive MITF recognition sequences (‘‘E boxes’’), which were
conserved among mammalian species. One E box was located
approximately 420 bp upstream of the transcriptional start site,
whereas a proximal E box was located within 20 bp of the start
site (Figure 3D). Another E box was located approximately 10 kb
upstream of these sequences, in the promoter sequences of anCancer Cell 23, 302–315, March 18, 2013 ª2013 Elsevier Inc. 305
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Figure 3. PGC1a Is Regulated by MITF in the Melanocytic Lineage
(A) Top ten transcription factors correlated to PGC1a mRNA in Lin et al. (2008). *q < 0.05.
(B and C) Requirement of MiT family members for PGC1a expression in M14 melanoma cells. Knockdown of each family member is shown in (B).
(D) Structure of PGC1a promoter inmammalian species showing the location of alternative (alt) exon 1 and exon 1. Also depicted are the locations of E box 1 and E
box 2 and primers used for ChIP.
(E) ChIP of indicated genomic region with anti-MITF, or rabbit IgG in primary melanocytes. Precipitated DNA was amplified using primers depicted in (D). ***p <
0.001 compared to rabbit IgG control.
(legend continued on next page)
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BRAF Regulates Metabolism via PGC1a and MITFalternative exon 1 (PGC1a-alt) (Miura et al., 2008; Chinsomboon
et al., 2009). To evaluate if MITF could directly bind to the
PGC1a promoter, we performed chromatin immunoprecipita-
tion (ChIP) using primers located either near alternative exon 1
or exon 1 (see Figure 3D). As shown in Figure 3E, MITF was
found to bind to the proximal PGC1a promoter but not to the
PGC1a-alt promoter in primary melanocytes. Due to limits in
the resolution of this assay, we were unable to distinguish if
MITF binds to E box 1, E box 2, or both. We therefore utilized
a PGC1a promoter cloned upstream of the luciferase reporter
gene (Handschin et al., 2003) and mutated each E box by
site-directed mutagenesis (Figure 3F). MITF overexpression
(Figure 3F) or treatment with PLX4720 (Figure 3G) led to the
induction of the wild-type promoter, whereas mutation of either
of the two E boxes significantly inhibited this response. Collec-
tively, these data indicate that MITF binds and directly regulates
the PGC1a gene in the melanocyte lineage. To evaluate if BRAF
regulates PGC1a via MITF, we suppressed MITF using siRNA,
then used PLX4720 to inhibit BRAF(V600E) activity. As shown
in Figure 3H, treatment with PLX4720 strongly induced
PGC1a mRNA in M14 cells and 3-fold in UACC62 cells, and
this induction was absent in cells in which MITF was knocked
down by siRNA. These data indicate that BRAF regulates
PGC1a via MITF.
BRAF Negatively Regulates MITF Activity
The relationship between BRAF and MITF is poorly understood
because oncogenic BRAF and the ERK pathway promote
MITF activation but also lead to its degradation (Hemesath
et al., 1998; Wu et al., 2000; Wellbrock and Marais, 2005; Well-
brock et al., 2008; Boni et al., 2010). We therefore examined
the consequences of ectopic BRAF(V600E) expression in
immortalized melanocytes. Introduction of oncogenic BRAF
was associated with decreased levels of M-MITF protein (the
melanocyte-specific isoform), but not other isoforms (Figure 4A).
Conversely, the MEK inhibitor PD0325901 induced the expres-
sion of TRPM1 and other direct targets of MITF in published
microarrays (Figure 4B) and by qPCR (Figure 4C). As shown in
Figure 4D, knockdown of MITF blocked induction of TRPM1,
suggesting these effects were dependent on MITF. In line with
these findings, we observed that treatment of UACC-257 cells
with PLX4720 for 72 hr led to increased pigmentation, reflecting
MITF’s essential role in melanin synthesis and pigmentation
(Figure 4E).
We were unable to detect a correlation between BRAF muta-
tion status and PGC1a or MITF expression in short-term
cultures. Given the prevalence of MAPK pathway mutations
other than BRAF(V600E) in melanoma, we evaluated the expres-
sion of PGC1a and MITF in melanomas with either high or low
expression of a MAPK activation gene signature. Both MITF (t
test, p = 1.43 1014) and PGC1a (t test, p = 1.343 105) expres-
sion inversely correlated with MAPK activity (Figure 4F). Collec-
tively, these data suggest that BRAF/MAPK inhibition leads to(F and G) Activity of PGC1a promoters upstream of the luciferase genemutated as
Gray boxes indicate the location of E boxes.
(H) Expression of PGC1a following knockdown of MITF (48 hr) and treatment wit
Error bars represent SEM of at least three independent replicates. **p < 0.0; ***p
See also Figure S3.activation of MITF mRNA and protein and that this induction
leads to induction of MITF targets including PGC1a.
To evaluate if BRAF suppression alters the BRAF/MITF/
PGC1a pathway described here in vivo, we obtained serial biop-
sies from 11 patients prior to treatment with BRAF/MEK inhibi-
tors and 10–14 days after beginning treatment (patient charac-
teristics described in Straussman et al., 2012). Of eight
samples that had detectable phosphorylated ERK at baseline
(Figure 5A), all had induction of PGC1a upon treatment (Fig-
ure 5B). Comparison to separately analyzed levels of M-MITF
induction following BRAF-targeted therapy revealed a significant
correlation to PGC1a induction within these patient-derived
specimens (J.A.W., unpublished data). Together, these data
indicate that the OXPHOS adaptive response described here
exists in vivo.
MITFPromotesExpression ofOxidative Phosphorylation
Genes
Up to 30% of melanomas harbor genomic amplifications of
MITF (Garraway et al., 2005), and MITF is required for the
survival of at least a subset of melanomas. Activating point
mutations have also been identified in melanoma (Bertolotto
et al., 2011; Yokoyama et al., 2011). These data have led to
the designation of MITF as a lineage-specific melanoma onco-
gene (Garraway et al., 2005). Comprehensive expression
profiling approaches have identified roles for MITF in promoting
cell growth and survival, organelle biogenesis, the oxidative
stress response, and miRNA regulation (Vachtenheim and Bor-
ovansky´, 2010; Haq and Fisher, 2011). However, a role for
MITF in regulating metabolism has not been previously
described. We therefore tested if MITF expression correlated
with oxidative phosphorylation by classifying melanomas into
two groups based on a previously defined oxidative phosphory-
lation signature. As seen in Figure 6A, melanomas with high
MITF expression had significantly higher oxidative phosphoryla-
tion gene expression (p = 5.51 3 105). Similarly, MITF expres-
sion correlated with PGC1a-regulated gene expression (p =
1.42 3 1015).
To evaluate if MITF was sufficient to drive oxidative phosphor-
ylation inmelanoma, we evaluated twomatched human cell lines
derived from primary melanocytes. These two cell lines (termed
pmel*+BRAF(V600E) and pmel*+BRAF(V600E)+MITF) are
derived from primary normal human melanocytes by immortali-
zation using telomerase, with a constitutively active allele of
cyclin-dependent kinase 4 and dominant-negative p53 (Garr-
away et al., 2005). These cells are therefore isogenic with the
exception of the expression of MITF. Consistent with published
reports by Garraway et al. (2005) and our results above, expres-
sion ofM-MITF protein was undetectable in pmel*+BRAF(V600E)
cells but strongly expressed in the derived MITF-expressing
cells, which correlated with PGC1a expression (Figure 6B).
BRAF(V600E) cells expressing MITF were able to form tumors
in immunocompromised mice, whereas control cells were notdepicted in response to transfection of MITF (F) or treatment with PLX4720 (G).
h PLX4720 (1 mM, 24 hr) in M14 cells (left) or UACC-62 cells (right).
< 0.001.
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Figure 4. BRAF Suppresses MITF Expres-
sion and Activity
(A) Levels of M-MITF (arrows) and phosphorylated
ERK in pmel* and pmel* BRAF(V600E).
(B) Effects of MEK inhibitor PD0325901 on MITF
mRNA and MITF targets by published microarray
(Pratilas et al., 2009).
(C) Response of MITF and MITF targets to
PLX4720 in UACC-257 cells by qPCR. *p < 0.01;
***p < 0.001 relative to DMSO control.
(D) Effect of MITF suppression on induction of
MITF-target TRPM1 by PLX4720. **p < 0.01; ***p <
0.001 relative to siControl. Error bars represent
SEM of at least three independent replicates.
(E) Consequence of PLX4720 (72 hr) on UACC-257
pigmentation. Equal number of cells were pelleted
by centrifugation.
(F) Box plots showing expression ofMITF (left) and
PGC1a in melanoma cells with high or low MAPK
activation from 88 short-term melanoma cultures
(Lin et al., 2008).
Cancer Cell
BRAF Regulates Metabolism via PGC1a and MITF(Figure 6C), paralleling previous data from soft agar growth
(Garraway et al., 2005). Similar to our findings with BRAF inhibi-
tion, GSEA of microarray data identified a highly significant
induction of the oxidative phosphorylation gene set in MITF-
expressing cells compared to control cells (q £ 0.0, p < 5 3
104; see Figure 6C). We found that a large majority of the oxida-
tive phosphorylation gene set was induced by MITF overexpres-
sion (Figure S4A), consistent with the ability of PGC1a to strongly
upregulate many oxidative phosphorylation genes (Mootha
et al., 2003). We validated the expression of differentially ex-
pressed genes (chosen to represent different mitochondrial
processes) by qPCR (Figure S4B) and found significant
increases in several oxidative phosphorylation genes. Similarly,
expression of the oxidative phosphorylation genes was sup-
pressed by oncogenic BRAF (Figure S4C).308 Cancer Cell 23, 302–315, March 18, 2013 ª2013 Elsevier Inc.To evaluate the metabolic conse-
quence of MITF overexpression directly,
we evaluated glycolysis and oxidative
phosphorylation in the isogenic cells.
Overexpression of MITF did not increase
glucose uptake (Figure 6D) but, strikingly
decreased lactate production (Figure 6E)
and increased oxygen consumption (Fig-
ure 6F), consistent with enhanced mito-
chondrial metabolism. Conversely,
BRAF(V600E) cells had elevated sensi-
tivity to knockdown of pyruvate kinase
(muscle isoform), the final step in the
glycolysis pathway, compared to
isogenic cells expressing MITF (Fig-
ure S4D), despite similar degrees of
knockdown efficiency in the two cell lines
(Figure S4E).
To further validate these findings in
patient-derived melanomas, we sup-
pressed MITF by shRNA and performed
gene expression profiling. We identified
several genes involved in oxidative phos-phorylation that were dependent on MITF (Figure S4F), consis-
tent with the aforementioned gene expression data. With the
exception of PGC1a, whose promoter was found to be directly
bound by MITF, oxidative phosphorylation genes were not
bound by MITF but have been identified as PGC1a targets in
other cell lineages (Mootha et al., 2003). We conclude that
MITF overexpression is sufficient and necessary to drive oxida-
tive metabolism and metabolic reprogramming in the melano-
cyte lineage.
BRAF Inhibition Leads to Bioenergetic Adaptation by
Induction of MITF and PGC1a
Collectively, the data above support the notion that BRAF inhibi-
tion endangers ATP production, which is rescued by concomi-
tant induction of MITF, PGC1a, and oxidative metabolism. To
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Figure 5. Validation of Induction of PGC1a Pathway In Vivo following
BRAF Inhibition
(A) Expression of phospho-ERK in eight matched patient biopsies prior or
during (10–14 days) treatment with BRAF/MEK inhibitors. Scale bar represents
100 mm.
(B) Expression of PGC1a mRNA prior and during treatment with BRAF/MEK
inhibitors. Error bars represent SEM of at least three technical replicates.
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BRAF Regulates Metabolism via PGC1a and MITFexperimentally test this hypothesis, we evaluated the response
of the isogenic cell lines expressing BRAF(V600E) with or without
M-MITF overexpression to PLX4032. Inhibition of BRAF resulted
in a 42% drop in ATP in BRAF(V600E) parental cells, whereas the
magnitude of this drop was reduced in MITF-overexpressing
cells (Figure 6G), despite similar basal ATP concentrations.
Consistent with MITF effects on oxidative metabolism,
BRAF(V600E)+MITF cells were significantly more sensitive to
the mitochondrial uncoupler 2,4-dinitrophenol (DNP; Figure 7A).
We also evaluated the magnitude of bioenergetic compensa-
tion in eight patient-derived melanoma cell lines. As shown in
Figure 7B, in all cases, there was induction of PGC1a following
vemurafenib treatment, which varied in magnitude by cell line.
We alsomeasured ATP levels before and after treatment with ve-
murafenib, and we observed a significant correlation between
induction of PGC1a and ATP levels in BRAF mutant cells (R =
0.72, p = 0.03; Figure 7C). Strikingly, the two lines with highest
ATP levels following BRAF inhibition are the ones with the stron-
gest induction of PGC1a. These data suggest that the metabolic
switch to ‘‘normal’’ varies in magnitude among different mela-
noma cell lines and suggest that the inhibition of BRAF leads
to a bioenergetic crisis that can be variably rescued by induction
of the MITF/PGC1a pathway.
We next asked whether oxidative metabolism could be ex-
ploited to inhibit the growth of melanoma cells. We compared
the sensitivity of melanoma cells to primary melanocytes (Fig-
ure S5). All melanoma cells were more sensitive to DNP than
primary melanocytes, except A375P. Treatment of UACC257
cells, but not A375P cells, with DNP led to a decrease in ATP
and increases in lactate, consistent with inhibition of OXPHOS
(Figures 7D and 7E). To validate the effects of mitochondrialinhibitors on tumor growth in vivo, we treated animals bearing
tumor xenografts of A375P and UACC257 melanoma cells with
DNP. Consistent with the in vitro data, we found that longitudinal
treatment of UACC257 xenografts profoundly inhibited tumor
growth, similar to the effects of PLX4032 (Figure 7F), whereas
A375P cells were insensitive to 2,4-DNP (Figure 7G).
Melanomas Treated with BRAF Inhibitors Are Addicted
to Oxidative Metabolism
Our observations thatBRAFandMITF regulatePGC1aexpression
promptedus toevaluate if oxidativemetabolismaffected response
to BRAF inhibitors. We observed that high levels of PGC1a were
associated with poorer prognosis in patients with stage III mela-
noma (Figure S6A) (Bogunovic et al., 2009). To this end, forced
expression of PGC1a protected cells from PLX4720, as demon-
strated using three cell lines that expressed low levels of PGC1a
(Figures 8A–8C). Because our data suggest that BRAF regulates
PGC1a and oxidative phosphorylation, we evaluated the effects
of inhibitors of oxidative phosphorylation in combination with
BRAF inhibitors. In addition, the cells were found to be relatively
insensitive to the mitochondrial uncoupler CCCP, but addition of
PLX4720 enhanced the cytotoxicity of this drug (Figure 8D). Mela-
noma cells treated with 2,4-DNP, or oligomycin A, which inhibits
oxidative phosphorylation through different mechanisms, addi-
tively enhanced the efficacy of PLX4720 in vitro (Figure 8E). We
also found similar data using rotenone and the complex II inhibitor,
TTFA (Figures S6B and S6C). Together, the data indicate that
induction of oxidative phosphorylation in response toBRAF inhibi-
tion limits the therapeutic efficacy of BRAF inhibitors.
DISCUSSION
Previous studies have suggested a role for BRAF signaling in the
regulation of tumor metabolism. Clinically, patients with BRAF
mutantmelanomas have higher levels of serum lactate consistent
with diminished oxidative phosphorylation (Board et al., 2009). In
addition, BRAF mutant melanomas have an order of magnitude
increased uptake of glucose compared to normal tissues in vivo
as assessed by functional imaging (Bollag et al., 2010). However,
the mechanism by which BRAF regulates metabolism in mela-
noma is poorly understood. This study identifies a pathway by
which the oncogenic BRAF pathway regulates energy metabo-
lism inmelanoma.OurfindingsshowthatBRAFactivation is asso-
ciated with diminished oxidative enzymes, diminished mitochon-
drial number and function, and increased production of lactate.
This metabolic reprogramming triggered by BRAF(V600E) is
accompanied by a suppression of MITF and PGC1a, a major
regulator of mitochondrial biogenesis and function.
We identify the melanocyte master regulator MITF as a direct
and essential mediator of BRAF-regulated PGC1a transcription.
Consistent with the restricted expression ofMITF to the melano-
cyte lineage, the ERK pathway does not appear to regulate
PGC1a transcription in BRAF mutant cancers that lack MITF
expression. The MITF-PGC1 connection thus explains the
lineage-specific effects of BRAF activation and inhibition.
Although BRAF inhibitors can suppress glycolysis and induce
oxidative phosphorylation, we found that MITF only regulates
mitochondrial respiration. Consistent with this, MITF and PGC1a
expression correlate with oxidative phosphorylation genes inCancer Cell 23, 302–315, March 18, 2013 ª2013 Elsevier Inc. 309
A B C
D E F G
Figure 6. MITF Regulates Oxidative Phosphorylation
(A) Box plots depicting MITF expression in melanomas with high expression of a PGC1a-target gene set (bottom) or oxidative phosphorylation gene set (top).
(B) Western blotting showing expression of MITF and PGC1a in pmel* BRAF(V600E) with and without MITF overexpression.
(C) Schema showing isogenic system evaluating the effect ofMITF overexpression in BRAF(V600E) melanoma cells. The tumorigenicity of the paired cell lineswas
assessed in FoxNnumice, and the number of formed tumors per injection of each cell line is shown. GSEA of the paired cell lines with themost highly induced gene
sets is shown (right).
(D–F)Glucoseuptake (D), lactate levels (E), andoxygenconsumption (F)weremeasuredas relative amounts in eachcell line, normalized tocell number. yp<0.0001.
(G) ATP levels, normalized to cell number in BRAF(V600E)+vector and BRAF(V600E)+MITF treated with PLX4032 (1 mM) for 24 hr.
***p < 0.001 compared to control cells. Error bars represent SEM of at least three independent replicates.
See also Figure S4.
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BRAF Regulates Metabolism via PGC1a and MITFa large series of melanoma short-term cultures, but we have not
observed an inverse correlation with glycolytic gene expression.
We also found thatMITF expression did not affect glucose uptake
but decreased lactate production and increased oxygen con-
sumption, consistent with a shift to oxidative metabolism. Thus,
consistent with Warburg’s initial hypothesis, the activation of
glycolysis and the suppressionofoxidativemetabolism,as shown
here to be initiated by oncogenic BRAF, are likely separate
processes.
Overall, our data suggest thatMITF is amajor regulator ofmito-
chondrial respiration in the melanocyte lineage by acting via
PGC1a. Tumors likely generate ATP via both glycolysis and
oxidative phosphorylation (Colombi et al., 2011; Weinberg
et al., 2010), and tumor cells may require mitochondria for func-
tions other than ATP generation, such as fatty acid synthesis
and glutaminolysis in some cases (Wise and Thompson, 2010;
Dang, 2012). However, we show here that MITF-expressing
melanomas have a higher level of oxidative gene expression.
These data therefore suggest that MITF expression may serve
as a biomarker for greater dependence on mitochondrial func-
tion. Because MITF has been difficult to drug directly (Haq and
Fisher, 2011), the dependence of MITF-dependent melanoma310 Cancer Cell 23, 302–315, March 18, 2013 ª2013 Elsevier Inc.on oxidative phosphorylation thus presents a theoretical thera-
peutic approach. However, MITF paradoxically can promote
tumorigenesis (e.g., Garraway et al., 2005; Yokoyama et al.,
2011), whereas activation of MITF expression in normal melano-
cytes typically induces differentiation, which likely antagonizes
tumorigenesis (D’Orazio et al., 2006; Carreira et al., 2006; Haq
and Fisher, 2011). A rheostat model has been proposed to
explain the apparent paradox of MITF (Goding, 2011), but defin-
itive evidence of this model remains an area of active investiga-
tion. We show that BRAF inhibitors induce some, but not all,
MITF target genes, implying that the context in which MITF is
regulated may also contribute to its physiologic effects. Finally,
it is also highly likely thatMITFhas protumorigenic effects outside
of its induction of OXPHOS, so that any antitumorigenic effect of
inducing OXPHOS may well be countered by other protumori-
genic effects. In the future, it will be of great interest to examine
how MITF can coordinate its numerous downstream effects.
Eight patients treated with vemurafenib had induction of
PGC1a,but a larger sample size will therefore be needed to eval-
uate the diagnostic and predictive role of PGC1a induction in
response to BRAF inhibitors. Interestingly, mutations in PGC1a
have been detected in recent melanoma whole-genome
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Figure 7. Effects of 2,4-DNP on Growth Melanoma Cells In Vitro and In Vivo
(A) Number of BRAF(V600E)+vector and BRAF(V600E)+MITF melanoma cells following treatment with 2,4-DNP with indicated dose for 72 hr.
(B and C) Levels of PGC1a mRNA (B) and ATP (C) in melanoma cell lines treated with vemurafenib (1 mM) for 24 hr.
(D and E) Effects of 2,4-DNP (50 mg/ml, 24 hr) on ATP (D) and lactate levels (E) in indicated cell lines in vitro. *p < 0.05.
(F and G) Effect of 2,4-DNP (20 mg/kg/day) or vemurafenib (75 mg/kg/day) on murine xenografts of indicated cell line (n = 7–8 per group).
**p < 0.01 and ***p < 0.001 compared to vehicle group. Error bars represent SEM of at least three independent replicates.
See also Figure S5.
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BRAF Regulates Metabolism via PGC1a and MITFsequencing efforts (Prickett et al., 2009; Stark et al., 2012). Our
data nonetheless suggest that dysregulation of PGC1a may
have profound effects on metabolism of melanoma cells and
may contribute to oncogenesis in certain cases.
We found that BRAF mutant melanomas treated with PLX4720
are dependent on ATP generation by mitochondria. Our data
suggest that inhibition of mitochondrial metabolism may be most
effective as initial therapy because most patients that have
relapsed following BRAF inhibitors have reactivation of the
MAPKpathway,whichwehaveshowncorrelateswithadecreased
level of MITF and PGC1a. Although mitochondrial function would
likely be difficult to target therapeutically in many cancer types,
agents that exploit bioenergetic andmetabolic alterations in mito-
chondria have been proposed by Fantin and Leder (2006). We find
that mitochondrial uncouplers enhanced the efficacy of PLX4720
in BRAF mutant melanomas, but demonstration of the in vivo effi-
cacy of this combination remains to be firmly established, which
possiblywill involve derivation of improvedmitochondrial pharma-
cologic agents. Although available drugs have generally unfavor-
able pharmacologic properties, 2,4-DNP had been used exten-
sively in diet pills (Cutting and Tainter, 1933), and over 100,000
people had been treated worldwide with the drug at the time of
its discontinuation (Tainter et al., 1934). Cases of dangerous side
effects such as fatal hyperthermia led to its official discontinuation
by 1938. Given the toxicities of the drugs, further development ofalternative oxidative phosphorylation inhibitors should be consid-
ered.Despite the recentsuccessesofBRAF inhibition in theclinical
arena, recurrence rates remain high, and survival is only extended
several months. Although further in vivo studies will be crucial,
uncouplers suchasDNP,or other inhibitors of oxidative phosphor-
ylation may be an alternative approach to enhance the effect of
BRAF inhibitors in patients with melanoma.
EXPERIMENTAL PROCEDURES
Gene Expression and Bioinformatics
Immortal melanocytes (pmel*) and their transformed counterparts, pmel*
BRAF(V600E)-vector and pmel*BRAF(V600E)+MITF, were maintained as
described by Garraway et al. (2005). Global gene expression analysis was
carried out using HG-U133A microarrays (Affymetrix).
RNA Isolation, ChIP, and Quantitative Real-Time PCR
ChIP was performed in primary human melanocytes using previously
described methods by Cui et al. (2007). Chromatin was immunoprecipitated
using rabbit polyclonal anti-MITF, or normal rabbit IgG as a control. Results
are normalized to input DNA.
Clinical Samples
All patients gave informed consent for tissue acquisition as per an IRB-
approved protocol (Office for Human Research Studies, Dana-Farber/Harvard
Cancer Center). Tumors were biopsied before treatment (day 0), at 10–14 days
during treatment.Cancer Cell 23, 302–315, March 18, 2013 ª2013 Elsevier Inc. 311
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Figure 8. BRAF Inhibitors Enhance Dependence on Mitochondrial Metabolism
(A–C) Sensitivity of A375M (A), WM1575 (B), and UACC-257 (C) melanoma cells overexpressing PGC1a to treatment with PLX4720 for 72 hr.
(D) Photograph of M14 cells treated with PLX4720 (5 mM), CCCP (20 mM), or the combination for 72 hr. Scale bar represents 100 mm.
(E) Cell number following treatment with mitochondrial uncouplers oligomycin A (1mM), CCCP (5 mM), or 2,4-DNP (200 mg/ml). Cell number was estimated after
72 hr of treatment.
*p < 0.05 and ***p < 0.001 compared to control. Error bars represent SEM of at least three independent replicates.
See also Figure S6.
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siRNAs SMARTpools (Dharmacon) were delivered using the lipidoid delivery
agent C12-133-B as described by Li et al. (2012).
Promoter Assays and Luciferase Experiments
The murine PGC1a promoter was obtained from Addgene. Mutagenesis was
performed using the QuikChange Site-Directed Mutagenesis Kit (Stratagene).
Mutant promoters were verified by sequencing. UACC-62 cells were trans-
fected with each promoter construct, pRL-CMV Renilla control, and aM-MITF
overexpression vector. PLX4720 treatment was for 48 hr. Results reported are
averages of at least three independent experiments, normalized for transfec-
tion efficiency using Renilla luciferase.
Xenograft Tumor Studies
All mouse experiments were done in accordance with Institutional Animal Care
and Use Committee-approved animal protocols at Dana-Farber Cancer Insti-
tute as described in the Supplemental Experimental Procedures.
Electron Microscopy
Electron microscopy of UACC-62 melanoma cells treated with vehicle or
PLX4720 (3 mM, 72 hr) was performed at the PMB Microscopy Core as
described in Supplemental Experimental Procedures.
ACCESSION NUMBERS
Expression array data are deposited under GEO accession GSE38007.312 Cancer Cell 23, 302–315, March 18, 2013 ª2013 Elsevier Inc.SUPPLEMENTAL INFORMATION
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